Sales of Edwards Lifesciences’ Sapien transcatheter aortic valve replacement (TAVR) systems have bounced back to pre-pandemic levels as hospitals have found ways to continue these life-saving procedures despite the risks of COVID-19.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?